The Pill and Pancreatic Cancer: What Women Need to Know
"A large-scale study investigates the link between hormonal birth control and pancreatic cancer risk in premenopausal women."
Pancreatic cancer is a formidable disease, known for its aggressive nature and high mortality rate. While relatively rare in younger women, understanding potential risk factors is crucial for informed health decisions. One area of ongoing research is the relationship between hormonal contraception and pancreatic cancer risk.
For years, women have relied on hormonal contraceptives for family planning and managing various health conditions. These medications, including birth control pills, patches, and intrauterine devices (IUDs), work by altering hormone levels in the body. Given the established role of hormones in various cancers, it's natural to wonder if hormonal birth control could influence pancreatic cancer risk.
A recent study published in PLOS ONE investigated this very question, focusing specifically on premenopausal women. The study aimed to determine whether hormonal contraception increases the risk of developing pancreatic cancer in this population. Here’s a breakdown of what the researchers found and what it means for women's health.
Current Burden and Evidence
SEER estimates that approximately 1.7 percent of men and women will be diagnosed with pancreatic cancer during their lifetimes, based on 2021–2023 data. In 2023, an estimated 113,931 people were living with pancreatic cancer in the United States. Research on oral contraceptives remains important because pancreatic cancer has limited identified modifiable risk factors, while oral contraceptives are widely used among women of reproductive age.
Evidence and Contraceptive Choice
The relationship between oral contraceptive use and pancreatic cancer risk remains controversial, with inconsistent findings in observational studies. A 2025 study described the need for more unbiased and robust approaches to clarify whether oral contraceptive use has a causal relationship with pancreatic cancer. Separately, the Society of Family Planning recommends access to all available contraceptive methods through a person-centered approach for individuals with a history of pancreatic cancer, among other gastrointestinal cancers.
From Discovery to Approval
Carl Djerassi first produced norethindrone, a synthetic progesterone, from yams in Mexico City nearly 65 years before the 2015 account. Oral contraceptives were initially approved by the U.S. Food and Drug Administration in 1957 to treat severe menstrual disorders and infertility. They were approved for birth control in 1960, after which debate about their risks and benefits continued.
Does Hormonal Birth Control Increase Pancreatic Cancer Risk?
The Danish study, a large-scale prospective cohort study, followed all women in Denmark aged 15-49 years without a history of cancer or venous thrombosis from 1995 to 2014. Researchers used the Danish National Prescription Registry to gather individually updated exposure information on hormonal contraception use.
- Types of Hormonal Contraception: Combined oral contraceptives, progestogen-only pills, patches, and IUDs.
- Duration of Use: How long women used hormonal contraception.
- Timing of Use: Whether women were current, recent, or past users.
- Potential Confounding Factors: Age, education, parity (number of births), age at first birth, smoking status, body mass index, polycystic ovary syndrome, and endometriosis.
Unresolved Evidence
The role of oral contraceptive pills and hormone replacement therapy among women with pancreatic cancer remains unclear, according to the cited dissertation. A systematic review and meta-analysis reported suggested protective effects of oral contraceptive use but stated that further epidemiological studies are needed to fully clarify the association. The National Cancer Institute also notes that many pancreatic cancer risk factors do not directly cause cancer but instead increase the chance of DNA damage that may eventually lead to cancer.
Duration Categories
The cited systematic review and meta-analysis presents a forest plot comparing pancreatic cancer risk across different durations of oral contraceptive use. The categories shown are less than one year, less than five years, five to ten years, and longer than ten years. The supplied source material identifies these comparison groups but does not provide the corresponding results, so no specific duration-related risk conclusion can be drawn here.
The Bottom Line
This study offers reassurance to women using hormonal contraception. The results suggest that current and recent use of contemporary hormonal contraception does not significantly increase the risk of pancreatic cancer compared to never-users. The risk also did not vary between users of combined and progestogen-only products. While this study provides valuable insights, it's essential to discuss your individual risk factors and concerns with your healthcare provider. They can help you make informed decisions about birth control based on your specific health profile.
Reproductive Factors and Risk
A hospital-based Case–Control Surveillance Study examined reproductive factors, oral contraceptive use, and postmenopausal hormone therapy in relation to pancreatic cancer risk. The study included 284 patients with pancreatic cancer and 1,096 controls. Its design reflects the broader challenge of evaluating associations between hormonal exposures and pancreatic cancer using observational data.
Evidence in Premenopausal Women
A cohort study specifically examined hormonal contraceptive use and pancreatic cancer risk among premenopausal women. This focus addresses how evidence about contraception and pancreatic cancer applies to women before menopause. The supplied source material identifies the study population and research question but does not provide its findings, so no direction or size of association can be stated from this source alone.